With the rise of personalized medicine, drug developers are relying more on novel biomarkers from assay development companies to improve their success.
We have extensive companion diagnostics experience across the world, including APAC, China, EMEA and US, and we have generated lab data supporting multiple successful CDx submissions and more than 150 CDx clinical trials engagements.
With our industry-leading science and innovative solutions, we have experience partnering with clients to advance development of their cell and gene therapy trials across numerous indications and development phases.
Expertise, experience, and tools for an optimized biomarker strategy throughout your product’s development life cycle.
As immuno-oncology drug development involves utilizing biomarkers more for targeted therapies, you need a laboratory services partner who can work with you to develop a successful biomarker-driven...
In this podcast, Dr. Patrice Hugo, Chief Scientific Advisor at Q2 Solutions discusses the selection and use of biomarkers in Immuno-oncology trials and the importance of early engagement between...
Alan Wookey, Companion Diagnostics and Oncology Scientific Advisor at Q² Solutions along with Kristina McGuire, Sr. Director & Head of CDx and Lab operations at Regeneron and Shirin Hasan, Associate,...